Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Allergy & Immunology
•
Asthma
•
Primary Care
What is your preferred biologic for an asthmatic patient with a T2 low phenotype and who is a smoker?
Related Questions
Should in-office oscillometry for lung function measurements be utilized in pediatric patients who are unable to reliably perform spirometry?
Which patient characteristics or scenarios drive you to choose tezepelumab over dupilumab for asthma?
Do you feel high dose Symbicort or Dulera is appropriate to use for SMART despite these doses not being studied in clinical trials?
When would you recommend prescribing an asthmatic patient budesonide/salbutamol rather than budesonide/formoterol?
Have you observed adverse mental health side effects in patients who start montelukast?
Do you recommend patients try antihistamines such as oral ketotifen that are not approved in the US but are approved in the EU for MCAS if currently available formulations have not been effective?
How do you decide when to add a second biologic agent to a patient’s asthma treatment who has either not responded or had a partial response to dupilumab, omalizumab, mepolizumab, or tezepelumab?
Do you avoid use of inhalers with milk protein in patients with a milk allergy?
Do you continue shots when a patient transfers under your care and has been receiving less than effective doses of AIT, but insist they have been effective?
How long do you counsel patients to wait after rituximab therapy before getting live vaccines?
